Table 1.
Preoperative and postoperative characteristics of the 172 matched patients.
| Characteristic | Group 1 | Group 2 |
|---|---|---|
| Adjuvant ADT | No adjuvant ADT | |
| Patients number | 86 | 86 |
| Median age (years) | 66.2 | 66.6 |
| Median Follow-up (months) | 69 | 66 |
| Mean PSA, ng/mL (range) | 31.5 (3–119) | 28.4 (2.78–159) |
|
| ||
| Clinical stage, 1997 TNM, (number (%)) | ||
| ≤cT2 | 36 (41.8%) | 48 (55.8%) |
| cT3 | 49 (57.0% ) | 37 (43.0%) |
| cT4 | 1 (1.2 %) | 1 (1.2%) |
|
| ||
| Biopsy Gleason score (number (%)) | ||
| ≤6 | 36 (41.8%) | 44 (51.2%) |
| 7 | 39 (45.3%) | 32 (37.2%) |
| ≥8 | 11 (12.9%) | 10 (11.6%) |
|
| ||
| Pathol. stage, 1997 TNM (number (%)) | ||
| pT2 | 4 (4.7%) | 9 (10.5%) |
| pT3a | 28 (32.5%) | 29 (33.7%) |
| pT3b | 50 (58.1%) | 45 (52.3%) |
| pT4 | 4 (4.7%) | 3 (3.5%) |
|
| ||
| Pathol. Gleason score (number (%)) | ||
| ≤6 | 34 (39.5%) | 34 (39.5%) |
| 7 | 39 (45.4%) | 39 (45.4%) |
| ≥8 | 13 (15.1%) | 13 (15.1%) |
|
| ||
| Surgical margins (number (%)) | ||
| Positive | 62 (72.1%) | 66 (76.7%) |
| Negative | 24 (27.9%) | 20 (23.3%) |
|
| ||
| Salvage therapy | ||
| ADT | 0 (0.0%) | 25 (29.1%) |
| Radiotherapy | 3 (3.5%) | 9 (10.5%) |
PSA: prostate-specific antigen; ADT: androgen deprivation therapy.